Skip to main content

8 Result(s)

within Y. Humblet Remove this filter

and

  1. No Access

    Article

    A phase I study of vinblastine tryptophan ester

    Vinblastine tryptophan ester (VTrpE) is a new vinca alkaloid derivative that achieves antitumor activity in a large variety of animal models. In this phase I study the drug was given as an i. v. injection over...

    F. Ceulemans, Y. Humblet, A. Bosly, M. Symann… in Cancer Chemotherapy and Pharmacology (1986)

  2. No Access

    Article

    Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC)

    Carboplatin, a second generation platinum complex, is less nephrotoxic and emetogenic than its parent compound. We have tested the objective response to and the toxicity of the combination carboplatin 330 mg m-2 ...

    P. Weynants, Y. Humblet, A. Bosly… in Medical Oncology and Tumor Pharmacotherapy (1990)

  3. No Access

    Article

    Tallimustine in advanced previously untreated colorectal cancer, a phase II study

    Tallimustine is a novel benzoyl mustard derivative from distamycin A with a unique mode of action. It is a DNA minor groove binder and produces highly sequence-specific alkylations. Previous studies have shown...

    CJA Punt, Y Humblet, E Roca, LY Dirix, R Wainstein, A Polli… in British Journal of Cancer (1996)

  4. No Access

    Article

    Clearance kinetics of CD34+ cells from peripheral blood: an independent predictor of hematologic recovery after high-dose chemotherapy and hematopoietic stem cell transplantation

    We measured the concentration of CD34+ cells in peripheral blood (PB) ½ h prior to and ½, 1, 3, 6, and 12 h following hematopoietic stem cell (HSC) infusion in 34 breast cancer patients treated with high-dose che...

    L D’Hondt, J Wuu, M André, C van Lerberghe, T Guillaume… in Bone Marrow Transplantation (1999)

  5. No Access

    Article

    Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients

     A total of 101 cancer patients with 121 febrile neutropenia episodes were randomised to receive empirical treatment with i.v. meropenem (1 g/8 h) or ceftazidime (2 g/8 h). After 3 days, 89% of patients were o...

    B. Vandercam, J. Gérain, Y. Humblet, A. Ferrant, G. Wauters… in Annals of Hematology (2000)

  6. Article

    Open Access

    Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab

    In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory metastatic colorectal cancer (mCRC). This analysis characterises the association of...

    S Siena, M Peeters, E Van Cutsem, Y Humblet, P Conte… in British Journal of Cancer (2007)

    Download PDF (210 KB) View Article

  7. No Access

    Article

    A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer

    Vinfunine (VFL) is a novel bifluorinated tubulin-targeted agent of the vinca alkaloids class active in advanced stage breast cancer. We conducted a phase I study combining VFL with doxorubicin (DXR) to define ...

    K. Zaman, X. Durando, J.-F. Baurain, Y. Humblet… in Breast Cancer Research and Treatment (2011)

  8. Article

    Open Access

    Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone

    Optimal preoperative treatment before colorectal cancer metastases (CRCM) resection remains unclear. This study evaluated pathological responses (pR) in CRCM resected after chemotherapy alone or combined with ...

    J Carrasco, M Gizzi, G Pairet, V Lannoy, P Lefesvre, J-F Gigot… in British Journal of Cancer (2015)

    Download PDF (759 KB) View Article